MGMihir Ghonge

Mihir Ghonge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mihir Ghonge has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Poorva H. Joshi

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA

    2 shared publications
  • Soumyajit Majumdar

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA; Research Institute of Pharmaceutical Sciences, University of Mississippi, University, MS 38677, USA

    2 shared publications
  • Ahmed Adel Ali Youssef

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA; Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt

    1 shared publication
  • Ahmed Adel Ali Youssef

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA

    1 shared publication
  • Corinne Sweeney

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA

    1 shared publication
  • Corinne Varner

    Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS 38677, USA

    1 shared publication

Latest Publications

  • Formulation and In Vitro-Ex vivo Evaluation of Cannabidiol and Cannabidiol-Valine-Hemisuccinate Loaded Lipid-Based Nanoformulations for Ocular Applications

    by Ahmed Adel Ali Youssef, Muna Hayder Abdelrahman, Mona M. Geweda, Corinne Varner, Poorva H Joshi, Mihir Ghonge, Narendar Dudhipala, Suresh P Sulochana, Rama S Gadepalli, Soumyajit Majumdar


  • Open Access

    Gatifloxacin Loaded Nano Lipid Carriers for the Management of Bacterial Conjunctivitis

    by Poorva H. Joshi, Ahmed Adel Ali Youssef, Mihir Ghonge, Corinne Varner, Siddharth Tripathi, Narendar Dudhipala, Soumyajit Majumdar

    Bacterial conjunctivitis (BC) entails inflammation of the ocular mucous membrane. Early effective treatment of BC can prevent the spread of the infection to the intraocular tissues, which could lead to bacterial endophthalmitis or serious visual disability. In 2003, gatifloxacin (GTX) eyedrops were introduced as a new broad-spectrum fluoroquinolone to treat BC. Subsequently, GTX use was extended to other ocular bacterial infections. However, due to precorneal loss and poor ocular bioavailability, frequent administration of the commercial eyedrops is necessary, leading to poor patient compliance. Thus, the goal of the current investigation was to formulate GTX in a lipid-based drug delivery system to overcome the challenges with the existing marketed eyedrops and, thus, improve the management of bacterial conjunctivitis. GTX-NLCs and SLNs were formulated with a hot homogenization–probe sonication method. The lead GTX-NLC formulation was characterized and assessed for in vitro drug release, antimicrobial efficacy (against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa), and ex vivo permeation. The lead formulation exhibited desired physicochemical characteristics, an extended release of GTX over a 12 h period, and was stable over three months at the three storage conditions (refrigerated, room temperature, and accelerated). The transcorneal flux and permeability of GTX from the GTX-NLC formulation were 5.5- and 6.0-fold higher in comparison to the commercial eyedrops and exhibited a similar in vitro antibacterial activity. Therefore, GTX-NLCs could serve as an alternative drug delivery platform to improve treatment outcomes in BC.


  • Recent Updates on Oral and Dermal Film-based Formulations and their Applications

    by Harsha Kathpalia, Saily Shinde, Mihir Ghonge

    On the one hand, oral formulations are susceptible to problems, including instability accompanied by erratic absorption throughout the gastrointestinal tract, first-pass metabolism, and patientrelated and pathological difficulties in consumption. On the other hand, the world has been observing a shift from conventional dermal formulations to the more cosmetically attractive ones. Amid all these, polymeric films and film-forming systems have emerged as promising candidates for addressing the above problems. Oral films have been studied for their potential applications in immediate and sustained- release formulations and have markedly shown increased plasma concentrations of drugs that otherwise undergo degradation in the gastrointestinal tract and the liver and have an obvious edge in treating pathologies of the oral cavity. At the same time, a variety of dermal film formulations have been developed and studied for treating wounds, skin infections and pathologies, corns and calluses, and managing pain. This review article attempts to cover significant findings in oral and dermal applications of these formulations under one umbrella and provide readers with a compilation of relevant research works and marketed formulations.